Supernus Pharmaceuticals (SUPN) Tax Provisions (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 12 years of Tax Provisions data on file, last reported at $2.2 million in Q4 2025.

• On a quarterly basis, Tax Provisions fell 80.18% year-over-year to $2.2 million in Q4 2025; TTM through Dec 2025 was -$10.5 million, a 143.75% decrease from a year earlier, with the FY2025 full-year figure at -$10.5 million, down 143.66% from the prior year.
• Tax Provisions for Q4 2025 stood at $2.2 million, up from -$12.8 million in the prior quarter.
• Over the last five years, Tax Provisions for SUPN reached as high as $25.9 million in Q3 2023 and fell as low as -$16.3 million in Q2 2023.
• Historically, Tax Provisions has averaged $1.7 million across 5 years, with a median of $2.8 million in 2022.
• Across the five-year window, Tax Provisions plunged 571.23% in 2023 and soared 6075.14% in 2024, its largest moves.
• Year by year, Tax Provisions stood at -$391000.0 in 2021, then surged by 2563.43% to $9.6 million in 2022, then plunged by 101.92% to -$185000.0 in 2023, then surged by 6075.14% to $11.1 million in 2024, then tumbled by 80.18% to $2.2 million in 2025.
• Per Business Quant data, the three most recent Tax Provisions figures were $2.2 million in Q4 2025, -$12.8 million in Q3 2025, and -$5.8 million in Q2 2025.